1:24-cv-01363 Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc., et al.
Case Summary
Heron Therapeutics, Inc. initiated litigation against Azurity Pharmaceuticals, Inc. and others under docket 24-cv-01363. The case has recently been assigned or reassigned, indicating the early procedural stage of the matter. Specific allegations or claims have not been disclosed in the available summary. Further details regarding the nature of the dispute, parties' claims, or court rulings are not currently available. The case remains pending with no substantive activity reported beyond administrative assignment.
Stage
Active litigation
Timeline
5 events
Coverage
5 articles
Sources
1
Key Issues
- • Case assignment
- • Parties: Heron Therapeutics vs. Azurity Pharmaceuticals
- • Early procedural status
Case Timeline
5 events1:24-cv-01363 Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc., et al.
A transcript was filed in the case between Heron Therapeutics, Inc. and Azurity Pharmaceuticals, Inc., which documents the proceedings or discussions that took place during a court session. This transcript provides an official record of what was said and can be used for reference in ongoing litigation. Having this record is crucial for ensuring transparency and accuracy in the legal process.
1:24-cv-10820 MERCK SHARP & DOHME LLC. et al v. ZYDUS PHARMACEUTICALS (USA), INC. et al
In a related case, Merck Sharp & Dohme LLC and others filed a lawsuit against Zydus Pharmaceuticals (USA), Inc. and others. This event highlights ongoing legal disputes in the pharmaceutical industry, which may impact the involved companies' operations and intellectual property rights. Understanding these cases is important as they can influence market competition and drug availability.
2:26-cv-03803 BAUSCH HEALTH IRELAND LIMITED et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al
The case titled BAUSCH HEALTH IRELAND LIMITED et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al was assigned or reassigned to a judge or court. This means the responsibility for overseeing the case has been officially designated, which is a routine but necessary step in the legal process.
1:25-cv-01555 Heron Therapeutics, Inc. v. Baxter Healthcare Corporation et al
A scheduling conference was held in the case involving Heron Therapeutics, Inc. and Baxter Healthcare Corporation. This meeting is used to set timelines and organize how the case will proceed. It helps ensure that both parties and the court are aligned on deadlines and key dates.
1:25-cv-01558 Bristol-Myers Squibb Company et al v. Azurity Pharmaceuticals, Inc.
In the case involving Bristol-Myers Squibb Company against Azurity Pharmaceuticals, the defendant has submitted an official response to the counterclaim filed by the plaintiff. This step is part of the legal process where the defendant addresses the allegations made against them. It matters because it moves the case forward by clarifying the positions of both parties.
Press Coverage
1:24-cv-01363 Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc., et al.
Transcript ( 209
1:24-cv-10820 MERCK SHARP & DOHME LLC. et al v. ZYDUS PHARMACEUTICALS (USA), INC. et al
2:26-cv-03803 BAUSCH HEALTH IRELAND LIMITED et al v. ZYDUS PHARMACEUTICALS (USA) INC. et al
Case Assigned/Reassigned
1:25-cv-01555 Heron Therapeutics, Inc. v. Baxter Healthcare Corporation et al
Scheduling Conference
1:25-cv-01558 Bristol-Myers Squibb Company et al v. Azurity Pharmaceuticals, Inc.
Answer to Counterclaim ( 17